In conclusion, based on the available evidence, the present study revealed that the administration of lapatinib in HER2-positive breast cancer in the neoadjuvant setting improves the probability of achieving a higher pCR rate, but is also associated with an increased risk of toxicity. This evidence concerns the gene ERBB2 and breast carcinoma.